Page 11 - Genentech News Today

Case Name: Genentech, Inc. v. Sandoz, Inc., Civ No. 23-4085 (JXN)(LDW), 2024 WL 939692 (D.N.J. Mar. 5, 2024) (Wettre, M.J.) - Drug Product and Patent(s)-in-Suit: Esbriet® (pirfenidone);...

Brody and Luke Mullins offer an exhaustive, telling, mesmerising chronicle of the biggest business in US politics

From far away anyone could see the gigantic two-story yellow bus on Purissima Street. It was parked right in front of the Ayudando Latinos a Soñar yellow home on 636

Overseas actors are exploiting the US university protests

After years of lackluster results, cancer vaccines seem poised for success. Finally.

With 50 biosimilar products approved by the FDA, questions arise regarding biosimilar lifecycles and sustainability of the industry.

Drug therapy workups may reveal candidates for immune therapy and provide chance for interventions.

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Report suggests several tools are inadequate, but app developers question the findings

Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.